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RCCClear renal cell carcinoma (cRCC) is an aggressive and fatal neoplasm. The present work was undertaken to
investigate the antiproliferative potential of vasoactive intestinal peptide (VIP) exposure on non-tumoral
(HK2) and tumoral (A498, cRCC) human proximal tubular epithelial cell lines. Reverse transcription and
semiquantitative PCR was used at the VIP mRNA level whereas enzyme immunoanalysis was performed at
the protein level. Both renal cell lines expressed VIP as well as VIP/pituitary adenylate cyclase-activating pep-
tide (VPAC) receptors whereas only HK2 cells expressed formyl peptide receptor-like 1 (FPRL-1). Receptors
were functional, as shown by VIP stimulation of adenylyl cyclase activity. Treatment with 0.1 μM VIP (24 h)
inhibited proliferation of A498 but not HK2 cells as based on a reduction in the incorporation of [3H]-thymidine
and BrdU (5′‐Br‐2′‐deoxyuridine), PCNA (proliferating‐cell nuclear antigen) expression and STAT3 (signal trans-
ducer and activator of transcription 3) expression and activation. VPAC1-receptor participation was established
using JV-1-53 antagonist and siRNA transfection. Growth-inhibitory response to VIP was related to the cyclic
adenosine monophosphate (cAMP)/exchange protein directly activated by cAMP (EPAC)/phosphoinositide 3-
kinase (PI3-K) signaling systems as shown by studies on adenylate cyclase stimulation, and using the EPAC-
speciﬁc compound 8CPT-2Me-cAMP and speciﬁc kinase inhibitors such as H89, wortmannin and PD98059.
The efﬁcacy of VIP on the prevention of tumor progression was conﬁrmed in vivo using xenografted athymic
mouse. These actions support a potential role of this peptide and its agonists in new therapies for cRCC.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Renal cell carcinoma (RCC) is a tumor thatmainly arises from renal tu-
bular epithelium [1] and represents about 90% of all renal malignancies
[2]. RCC is the most frequent and lethal malignant tumor of the kidney
and the third most commonmalignancy in the ﬁeld of urological oncolo-
gy [3]. Surgical resection of the tumor is considered the only curative
treatment [4]. In fact, metastatic RCC is refractory to chemotherapy due
to the expression ofmultidrug resistance transporters in proximal tubules
[1]. The response to radiotherapy is also negative, whereas cytokine-
based immunotherapy elicits some beneﬁts in about 20% of patients [5].
Molecular markers with potential diagnostic and prognostic value are
not clearly deﬁned in RCC as tumor targets at which a new therapy can
be aimed have not been deﬁned [6]. One approach to control RCC is theandMolecular Biology, Faculty
8871 Alcalá de Henares, Spain.
).
l rights reserved.inhibition of cell growth, but the results available are limited. Thus, effec-
tive therapies for advanced RCC are needed to improve patient prognosis.
Signal transducer and activator of transcription (STAT) factor is an
important point of convergence for various signaling pathways that are
activated in the malignant transformation of many human tissues [7].
STATs are a family of transcription factors that are often stimulated in re-
sponse to the activation of receptors for cytokines, chemokines and
growth factors through Janus kinases (JAKs) as well as an increasing
number of G protein-coupled receptors (GPCRs) [8,9]. STAT3 is the
most studied STAT protein. Constitutive activation of STAT3 has been ob-
served in many types of cancer [10]. STAT3 is a positive regulator of
tumor cell proliferation, cell motility and anti-apoptotic genes [11,12].
The activation of STAT3 has been associated with progression of RCC
and poor survival [13], but its role as a prognostic marker for this disease
remains elusive as studied by an assessment of itsmRNA expression [14].
Vasoactive intestinal peptide (VIP), a neuropeptide widely expressed
throughout the body, is a member of the pituitary adenylate cyclase-
activating polypeptide (PACAP)/secretin/glucagon family of peptides.
VIP exerts a wide range of biological effects acting through PAC1, VPAC1
1677E. Vacas et al. / Biochimica et Biophysica Acta 1823 (2012) 1676–1685and VPAC2 receptors [15,16]. VPAC1 and VPAC2 receptors are G-protein
coupled heptahelical receptors that lead mainly to the activation of the
cAMP signal-transduction system but are also involved in other intracel-
lular pathways [12,16]. Recently, it has been reported that VIP is a func-
tional ligand for formyl peptide receptor-like 1 (FPRL-1) in human
monocytes [17]. While cAMP signaling has classically been associated
with the activation of protein kinase A (PKA), many effects of VIP do
not rely solely upon PKA signaling. In this context, cAMP also directly
regulates the exchange protein directly activated by cAMP (EPAC), a
guanine nucleotide exchange factor (GEF) that is a crucial mediator of
PKA-independent cAMP signaling [17,18].
Previous observations on PACAP effects in renal cells have provided
some evidence that this VIP-related peptidemay induce renoprotective
effects. Thus, PACAP protects against oxidative stress in primary rat kid-
ney culture [19]. Moreover, PACAP behaves as a cytoprotective agent in
multiple myeloma and other kidney diseases [20]. These features to-
gether with observations on the inhibitory effects of VIP on cell prolifer-
ation in tumors such as neuroblastoma [21] or hepatocellular carcinoma
[22] prompted us to study the action of VIP in renal cell carcinoma. An
inhibitory effect of VIP on the growth and progression of this carcinoma
could be considered to develop new therapies. Here, we used human
renal cell cultures (non-neoplastic HK2 and neoplastic A498 cells (clear
cell RCC) in order to characterize theVIP-receptor systemand its possible
relation with cellular processes typically associated with cell prolifera-
tion and cancer progression.
2. Materials and methods
2.1. Cell culture
The human renal proximal tubular epithelial cell line HK2 and the
human renal carcinoma cell lineA498were purchased from theAmerican
Type Culture Collection ATCC (Rockwell, MD, USA). HK2 cells were cul-
tured in complete DMEM/F12 medium (Invitrogen, Barcelona, Spain),
ITS and L-glutamine. A498 cells were cultured in Eagle's Modiﬁed Medi-
um. Both media were supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin/amphoterycin B. Cell culture was performed
in a humidiﬁed 5% CO2 environment, at 37 °C. After cells reached
70–80% conﬂuence, they were washed with PBS, detached with
0.25% trypsin/0.2% EDTA, and plated at 30,000–40,000 cells/cm2. The
culture medium was changed every 2 days.
2.2. RNA isolation and semiquantitative reverse transcription-PCR (RT-PCR)
HK2 and A498 cells were placed in 6-well plates (15·104 cells per
well) and maintained in their medium for 24 h. Cultured cells were
stimulated with 0.1 μMVIP for different times. Then, total RNAwas iso-
lated with Tri Reagent (Sigma-Aldrich, Alcobendas, Spain) according to
the instructions of the manufacturer. Two micrograms of total RNA
were reverse-transcribed using 6 μg of hexamer random primer and
200 UM-MLVRT (Life Technologies, Barcelona, Spain) in the buffer sup-
plied with the enzyme supplemented with 1.6 μg/ml oligo dT, 10 nM
dithiothreitol (DTT), 40 U RNasin (Promega Madison, WI, USA), and
0.5 mM of deoxyribonucleotides (dNTPs). Two microliters of the RT re-
action were used for each PCR ampliﬁcation with a primer set which
ampliﬁes cDNAs for human cysteine rich protein with STAT3, VIP or
β-actin. The corresponding sequences of oligonucleotide primers were:
STAT3 (sense 5′-AGT GAG TAA GGC TGG GCA GA-3′ and antisense 5′-
AAG GCA CCC ACA GAA ACA AC-3′), VIP (sense 5′‐ACG TCA CTC AGA
TGC AGT CTT CAC-3′ and antisense 5′-TGC TCC TCT TTC CAT TCA GAA
TT-3′), and β-actin (sense 5′-AGA AGG ATT CCT ATG TGG GCG-3′). PCR
conditions were: denaturation at 94 °C for 5 min, followed by
26–40 cycles of 95 °C for 1 min, 57 °C for 1 min, 72 °C for 1 min, and
then a ﬁnal cycle of 10 min at 72 °C. The signals were normalized to
the β-actin gene expression level. PCR productswere separated by elec-
trophoresis and visualized in 2% agarose gels. The bands were cut fromthe gel, eluted, and automatically sequencedwith an ABI 377 sequencer
(Applied Biosystems, Alcobendas, Spain).
2.3. VIP enzyme immunoanalysis (EIA)
HK2 and A498 cells were placed in either 24-well plates (6×104 cells
per well) to obtain extracellular secretion or 6-well plates (15×104 cells
perwell) to obtain cytosolic extracts andmaintained in theirmedium for
24 h. Cultured cells were stimulated with 0.1 μM VIP at different
times. Thereafter, extracellular secretion was collected and cells
placed in 6-well-plates were lysed with 10 mM HEPES (pH 7.9),
10 mM KCL, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM phe-
nyl methylsulfonylﬂuoride (PMSF), 10 μg/ml protease inhibitors, 5 mM
NaF, 1 mM Na3VO4, and 1 mM NaN3. Cells were kept on ice for 15 min,
then 0.5%Nonidet P-40was added and the cytosolic extract was pelleted
by centrifugation at 25,000×g for 40 s at 4 °C. VIP levels were quantiﬁed
by EIAwith a commercially available kit according to themanufacturer's
instructions (Phoenix Pharmaceutical, Karlsruhe, Germany). The antise-
rum had 100% cross-reactivity with human VIP and VIP.
2.4. Confocal immunoﬂuorescence microscopy
HK2 and A498 cells were placed in 24-well plates (40–60×103 cells
per well) on glass coverslips. The cells were ﬁxed for 25 min at room
temperaturewith 4%paraformaldehyde in PBS. Then, theywere perme-
abilized with 0.1% Triton X-100 for 10 min at room temperature and
blocked with 3% bovine serum albumin (BSA) for 1 h. Afterwards, cells
were incubated for 1 h at room temperature with rabbit antisera against
VPAC1, VPAC2, and PAC1 receptors (Afﬁnity Bioreagents, Golden, CO,
USA), and antibodies to FPRL-1 receptors (Abcam, Cambridge, UK).
After washing with PBS, cells were incubated with goat anti-rabbit-
FITC secondary antibody (1:2000) (Alexa, Invitrogen, Barcelona, Spain)
for 1 h in darkness. Cells were washed again in PBS and the coverslips
were mounted with FluorSave™ Reagent (Calbiochem, San Diego, CA).
Color detection was performed with a LEICA TCS-SL confocal laser scan
microscope.
2.5. Protein isolation
HK2 and A498 cells (1–2×106 cells in 100 mm cell culture dishes)
were incubatedwith 0.1 μMVIP (NeoMPS, Strasbourg, France) for differ-
ent time periods. The cells were washed twice with ice-cold PBS and
then harvested, scraped into ice-cold PBS, and pelleted by centrifugation
at 500×g for 5 min at 4 °C. The cells were kept on ice for 30 min in a so-
lution containing 20 mM Tris–HCl (pH 7.5), 1 mM EDTA, 0.5 M NaCl,
0.5% Nonidet NP-40, 2 mM PMSF, and 10 μg/ml protease inhibitors.
Thereafter, the cells were pelleted by centrifugation at 4000×g for
5 min at 4 °C.
2.6. Western blotting
Protein content was measured by the Bradford assay using BSA as a
standard. Protein (10–50 μg) from cell lysates was solubilized in 50 mM
Tris–HCl buffer (pH 6.8) containing 10% (v/v) glycerol, 3% (w/v) SDS,
0.01% bromophenol blue, and 0.7 M β-mercaptoethanol, and then heat-
ed at 95 °C for 5 min. Proteins were resolved by 10% SDS-PAGE, and
transferred to nitrocellulose sheets (BioTrace/NT, Pall Corporation,
East Hills, NY, USA). Rabbit monoclonal antibodies to VPAC1 receptor
(1:10,000) (Afﬁnity Bioreagents), FPRL-1 receptor (1:5000) (Abcam),
proliferating-cell nuclear antigen (PCNA) (Dako, Glostrup, Denmark),
pSTAT3 and STAT3 (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were added followed by incubation for 1 h or overnight. After
treatment for 1 h at room temperature with the corresponding HRP-
labeled secondary antiserum (1:4000) (BD Biosciences, Bedford, MA,
USA), the signals were detected with enhanced chemiluminescence
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(Merck, Darmstadt, Germany) as a loading control.2.7. Adenylyl cyclase activity
The ability of VIP and forskolin to cause elevation of cAMP levels was
determined in HK2 and A498 cells. Human renal cells were placed in
6-well plates (3×105 cells per well) and treated with 750 μl of medium
supplemented with 1% BSA, 1 mg/ml bacitracin, 0.05 mM PMSF and
0.4 mM3-isobutyl-1-methylxanthine (IBMX). After 15 min of treatment
with increasing concentrations of VIP and forskolin, the mediumwas re-
moved and then 70% ethanol was added. Themixture was transferred to
fresh tubes and evaporated at 60 °C. Dried samples were dissolved in
0.2 M phosphate buffer and stored at−20 °C until further assays. After-
wards, cAMP levels were measured using a competitive binding assay
[23].2.8. Cell proliferation assay with [3H]-thymidine
HK2 and A498 cells were placed in 24-well plates (104 cells per well)
and maintained in medium for 24 h. Then, they were stimulated with
0.1 μMVIP for 24 h in the presence of [3H]-thymidine (0.4 μCi/ml). After-
wards, the cells were washed twice with PBS and cells were incubated
with trichloroacetic acid 5%, for 15 min, at 4 °C, in the darkness. The
cells were washed again with methanol and solubilized by adding
0.1 MNaOH and 0.1% SDS. Then, 0.4 ml of the cell solutionwas collected,
placed into 4-ml scintillation vials, and counted for radioactivity.2.9. Cell proliferation assay with 5′-Br-2′-deoxyuridine (BrdU)
HK2 and A498 cells were placed in 6-well plates (15×104 cells per
well) and maintained in medium for 24 h. Cells were treated with VIP,
PACAP38, 8-pCPT-2′-O-Me-cAMP or forskolin for 24 h. Moreover, they
were cultured for 24 h with JV-1-53, a GHRH analog which behaves as a
VIP antagonist [24,25] or preincubatedwith one of three different protein
kinase inhibitors: PKA inhibitorH89 (15 min),MEK1/2 inhibitor PD98059
(1 h) or PI3‐K inhibitor wortmannin (30 min), and VIP 0.1 μM, for 24 h.
The cells were pulsed with 10 μM BrdU, (BD Bioscience) during the last
30 min of incubation. Afterwards, the cells were washed with PBS and
ﬁxed with ice-cold absolute ethanol, at−20 °C, for 30 min. Fixative was
removed by centrifugation and the cell pellets were washed with PBS.
DNA was partially denatured by incubation with 2 M HCl for 30 min at
room temperature, after which the cells were washed three times with
PBS containing 0.05% Tween-20 (pH 7,4) and 0.1% BSA. Cells were incu-
bated for 30 min with 20 μl of anti-BrdU monoclonal antibody with FITC
(BD Bioscience) in the dark. The cells were stained with PI staining solu-
tion (50 μg/ml PI, 10 μg/ml RNase, 1× PBS), before ﬂow cytometric anal-
ysis. DNA distribution in the different phases of the cell cycle was
analyzed with the use of the Cyﬂogic v. 1.2.1 program.2.10. Transfection of VPAC1-receptor siRNA
HK2 and A498 cells were seeded in medium without antibiotics in
100 mm cell culture dishes (6×105 cells per well) and maintained for
24 h. The next day, cells were transfected with VPAC1-receptor siRNA
(150 nM), using Lipofectamine 2000 (Invitrogen), as per the man-
ufacturer's instructions. The oligomer–lipofectamine complexes were
added to the cells. After 8 h, the transfection medium was changed to
fresh culture medium and the cells were then assayed for levels of
VPAC1-receptor protein and cell proliferation. A nonsilencing RNA duplex
(Ambion) was used as a control. The effective sequences were 5′-GGA
GGA GUG UAG CUA UGU G-3′ for duplex 1, and 5′-CAC AUA GUC ACA
CUC CUC C-3′ for duplex 2.2.11. Animals and preparation of A498 cell xenografts
Athymic nude (nu/nu) 4 week-old male mice were purchased from
Harlan Iberica Laboratory (Barcelona, Spain) andmaintained under spe-
ciﬁc pathogen-free conditions. We obtained approval from the Institu-
tional Animal Care and Use Committee of Alcala University. Mice were
housed in Plexiglas cages (four/cage), kept at 20 °C with a 12-h light/
dark cycle, and fed autoclaved standard chow and water ad libitum.
A498 cells were preincubated in the absence or presence of 3 μM VIP
antagonist, JV-1-53 for 10 min, and then they were incubated in the ab-
sence or presence of 1 μM VIP for 1 h. Afterwards, cells were washed
with PBS, detached with 25% trypsin/0.2% EDTA, centrifuged at 400×g,
and resuspended in fresh medium. Cell suspension was mixed with
Matrigel (BD Bioscience) synthetic basement membrane (1:1, v/v) and
then injected under the skin in the abdomen (5×106 cells/mouse). Six
animals were used per group. Tumors were harvested after sacriﬁce at
3 weeks of subcutaneous cell injection.
2.12. Data analysis
Quantiﬁcation of band densities was performed by using the Quan-
tiﬁedOne Program (Bio-Rad). Data shown in the ﬁgures are representa-
tive of at least three different experiments. The results are expressed as
the mean±SEM and were statistically treated following a Bonferroni's
test for multiple comparisons after one or two-way analysis of variance
(ANOVA). The level of signiﬁcance was set at Pb0.05.
3. Results
3.1. VIP mRNA and peptide levels
Non-tumor (HK2) and tumor (A498) humanproximal tubular epithe-
lial cell lines were investigated for the expression of mRNA for VIP by
semiquantitative RT-PCR as well as for VIP protein by EIA procedures.
Semiquantitative RT-PCR analysis of VIP mRNA expression yielded a
product of the expected size for both cell lines. The expression of mRNA
for β-actin was used as internal control. Fig. 1 shows that both mRNA
for VIP and peptide VIP were overexpressed in tumor cells. In the second
case, the increase of peptide levels in A498 cellswas seen in both cytosolic
fraction and extracellular medium which indicates that tumor cells are
more active than non-tumor cells in the production and secretion of VIP.
3.2. Effect of exogenous VIP on intracellular VIP levels and VIP secretion
In order to investigatewhether VIP increases its own expression and
secretion, VIP levels were measured by EIA in both intracellular and ex-
tracellular media from HK2 and A498 cells that had been incubated in
the absence or presence of 0.1 μM VIP for different times. The results
showed that cytosolic VIP levels were maximal at 2 h in both cell lines
(Fig. 2, upper panels). These increases in cytosolic VIP levels were con-
ceivably a result of an increased expression of the neuropeptide. In
order to determine whether these elevated levels in the intracellular
compartment were accompanied by an enhancement of VIP secretion,
EIA was performed in the secreted medium. As shown in Fig. 2 (lower
panels), the results indicated that extracellular VIP reached maximal
levels at 16 h and 8 h in HK2 and A498 cells, respectively.
3.3. Expression of VIP receptors
The expression of VIP receptors was determined in both non-tumor
HK2 and tumor A498 cells bymeans of immunocytochemistry using spe-
ciﬁcs antibodies. Both cell lines expressed VPAC1, VPAC2 and PAC1 recep-
tors, whereas FPRL-1 receptor was only expressed in HK2 cells (Fig. 3).
VPAC1was highly expressed at the nuclear level in both cell lines, where-
as VPAC2 and PAC1 receptors were expressed in both cells lines but they
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Fig. 1. A: Expression of VIP mRNA in HK2 and A498 cells as studied by semiquantitative RT-PCR. PCRs yielded products of the expected size (101 bp). All preparations were nor-
malized according to the expression of β-actin mRNA. B: Expression of VIP (cytosolic fraction) as measured by ELISA. C: Expression of VIP (extracellular medium). Data are the
means±S.E. of at least three experiments. *Pb0.05.
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be expressed in the plasma membrane fraction of HK2 cells.3.4. Coupling of VIP receptors to the cAMP system
The cAMP molecule is recognized as the major second messenger of
the VIP-receptor system. The ability of VIP to stimulate cAMP production
in both human proximal tubular epithelial renal cells studied proved the
functionality of VIP receptors (Fig. 4A). The response to VIP was dose-
dependent and qualitatively as well as quantitatively similar in HK2
andA498 cells. Forskolin, a diterpene that interactswith adenylyl cyclase
in a direct way, also increased cAMP levels by a dose-dependent mecha-
nism in both cell lines (Fig. 4B).0
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sured in extracellular medium by EIA. Data are the means±S.E. of at least ﬁve experiment3.5. Effect of VIP on cell proliferation
The study of mitochondrial functionality indicated that VIP did not
modify cell viability in any cell line studied. This ﬁnding indicated that
VIP did not exert cytotoxic effects in renal cells. Indeed, treatment with
VIP did not induce apoptosis or necrosis as indicated by ﬂow-cytometry
analysis of human proximal tubular epithelial cell lines labeled with
propidium iodide and annexin V (results not shown).
The effect of VIP on the proliferation of HK2 and A498 cells was esti-
mated by means of [3H]-thymidine and BrdU incorporation assays.
Treatment for 24 h with 0.1 μM VIP ([3H]-thymidine assays) (Fig. 5A)
or increasing VIP concentrations (BrdU assays) (Fig. 5B) resulted in a
signiﬁcant decrease of cell proliferation in A498 cells, as compared
with untreated controls. However, VIP treatment did not modify cell0
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the analysis of the expression of PCNA (Fig. 5C): treatment with 0.1 μM
VIP for 1 h resulted in a decrease of about 25% of PCNA levels after
1–2 h in A498 cells but HK2 were unaffected. Thus, VIP appears to be in-
volved in antiproliferative mechanisms in renal cell carcinomas but not
in benign renal tissues.
3.6. Effect of VIP on STAT3 expression
Wealso determinedwhether VIP regulated STAT3 expression at both
mRNA and protein levels. For this purpose, HK2 and A498 cells were
treated with 0.1 μM VIP for different times. Semiquantitative RT-PCR
for STAT3 (Fig. 6A) and measurement of pSTAT3/STAT3 protein levels
by means of Western blot analysis (Fig. 6B) followed by densitometry
were then carried out. Renal cell carcinoma A498 cells, but not HK2
cells, showed a decrease of STAT3mRNA expression. In addition, VIP de-
creased phosphorylation and activation of STAT3 in tumor cells, but not
in HK2 cells. These ﬁndings on effects of VIP on STAT3 expression corre-
late with the observations on VIP regulation of cell proliferation in renal
cell carcinoma.
3.7. Involvement of VPAC1-receptor on renal cell carcinoma proliferation
In order to characterize VPAC1 receptor (the main VIP receptor) in-
volvement in proliferation of renal tumor cells, A498 cells were treated
with 0.3 μM VIP antagonist, JV-1-53 for 24 h in the absence or presence
of 0.1 μMVIP. After a 30 min incubationwith 10 μMBrdU, measurement
of cell proliferation by BrdU incorporation assay showed that the inhibito-
ry effect was blocked by JV-1-53 (Fig. 7A), suggesting the involvement of
VPAC1 receptor. To further establish the participation of VPAC1-receptors
in renal cell carcinoma proliferation, A498 cells were transfected with
VPAC1-receptor siRNA. The study of the expression of the receptor by
Westernblot showedadrastic decrease (by95%)ofVPAC1-receptor levels
(Fig. 7B). Moreover, transfected A498 cells presented an increased
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ment of VPAC1 receptor in activation of STAT3 protein activation. Finally,
the effect of VPAC1 receptors on tumor cell proliferationwasmeasured by
means of BrdU incorporation assays in transfected A498 cells. The results
showed a signiﬁcant increase in the proliferation extent of transfected
cells as compared to negative, non-transfected cells (Fig. 7C).3.8. Signal transduction pathways involved in VIP effect on cell proliferation
To explore whether the effect of VIP on A498 cell proliferation is
related with EPAC-mediated pathways, cells were incubated for 24 h
with 0.1 μM VIP, 300 μM 8-pCPT-2′-O-Me-cAMP or 0.1 μM forskolin
(Fig. 8A). Thereafter, the cells were incubated with 10 μM BrdU
and cell proliferation was measured by BrdU incorporation assay.
The involvement of the cAMP/EPAC pathway was conﬁrmed by the
observation of the inhibitory effects of forskolin and 8-pCPT-2′-O-Me-
cAMP upon cell proliferation.
To evaluate the speciﬁcity of the signaling pathways that could be
involved in the VIP effect on the proliferation of renal carcinoma cells,
A498 cells were cultured in the absence or presence of 0.1 μMVIP and
different protein kinase inhibitors: PKA inhibitor H89, MEK1/2 inhib-
itor PD98059, or PI3‐K inhibitor wortmannin. Again, the cells were in-
cubated with 10 μM BrdU and cell proliferation was measured by BrdU
incorporation assay. As shown in Fig. 8B, cell treatment with 0.1 μM
wortmannin fully abolished the inhibitory effect of VIP upon prolifera-
tion of A498 cells, whereas 10 μM PD98059 had no effect and 10 μM
H89 resulted in decreased cell proliferation. These results support that
PI3‐K plays a role in mediating the inhibitory effects of VIP on prolifer-
ation of A498 cells.3.9. VIP prevention of tumorigenesis by A498 cells in xenografted athymic
mice
The efﬁcacy of VIP on the prevention of tumor progression was also
studied in vivo. Using xenografted athymic mouse, we observed that
growth of the tumor mass was initiated as soon as 2 days after the inoc-
ulation of tumoral A498 cells and all groups developed tumors. Also, cells
treated with the neuropeptide (1 μMVIP for 1 h) presented a signiﬁcant
decrease (30%) in their ability to develop tumor growth as shown from
the beginning of development. The inhibitory effect of VIP upon develop-
ing tumors was reverted by using A498 cells that had been preincubated
with the antagonist JV-1-53 (3 μMVIP antagonist for 10 min), which in-
dicates the involvement of VPAC1-receptor in the antitumoral effect of
the neuropeptide (Fig. 9).
4. Discussion
In this study, we demonstrate for the ﬁrst time that VIP inhibits the
proliferation of A498 human renal carcinoma cells both in vitro and in
vivo. The use of different experimental approaches to generate ourﬁnd-
ings as well as the observations of the role of EPAC/STAT3 signal trans-
duction system in VIP activity support this conclusion. These results
together with the detection of the expression of VIP and its receptors
in renal tumor cells provide molecular basis for potential development
of new therapies for renal cancer.
Present results are in apparent conﬂict with previous reports on the
stimulatory effect of VIP on cell proliferation and related events in normal
and tumor cells [26–29]. Thus, we have demonstrated that VIP induces
promotion and progression of human prostate carcinoma and potentiates
the production of key proteins involved in development of metastasis
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human breast carcinoma [30–32]. These responses are the result of inter-
action of VIP with its receptors, mainly VPAC1 receptors, which are
coupled through Gs proteins to adenylyl cyclase activation. The resulting
cAMP increase leads to PKA activation, phosphorylation of protein sub-
strates, and potentiation of oncogene expression [16,33]. In addition toB)A498
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alternative signaling models as EPAC/STAT3 studied here. Thus, the oc-
currence of different receptor molecules for VIP together with the com-
plex array of intracellular signaling pathways that can be activated after
VIP-receptor activation explains the observation of apparent discrepan-
cies such as the opposite effects of the neuropeptide on cancer cell
proliferation depending on the affected organ.
Weused non-tumoral HK2 and tumoral A498 renal cells. Both human
cell lines expressed VIP, as assessed by mRNA and peptide determina-
tions, and VIP secretion towards extracellular medium was higher in0.0
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tide, 0.1 μM VIP for 24 h. In agreement with previous results [28], VIP
had no toxic effects on cell viability that could mask the observed re-
sponses. The study of mitochondrial functionality as well as cell cycle
analysis by ﬂow cytometry excluded the possibility of apoptosis or ne-
crosis due to VIP treatment. Interestingly, the neuropeptide inhibited
the proliferation of tumor cells but it did not affect non-tumoral cell
growth as indicated by assays on [3H]-thymidine and BrdU incorpora-
tion as well as measurement of PCNA levels. These results are in close
agreement with our parallel observations on STAT3 expression and ac-
tivation. STAT3 appears to be involved in oncogenic transformation
through gene transcription in antiapoptotic pathways, as shown in var-
ious cancer types including renal cell cancer [11–13]. Down-regulation
by VIP of STAT3 expression in malignant A498 but not in non-tumoral
HK2 renal cells and inhibition by VIP of STAT3 activation (by phosphor-
ylation) in A498 cells support the view that the neuropeptide exerts its
antiproliferative effects in tumor renal cells through the inhibition of
both STAT3 and pSTAT3 levels.
Since STATs are a major point of convergence for different signaling
systems that are activated in tumor cells [7], it is mandatory to deﬁne
upstream signals that connect with VIP in renal cancer cells. First of
all, the major role of VPAC1 receptor in the antiproliferative activity of
VIP on A498 cells emerges from our observationwith the VIP antagonist
JV-1-53, a GHRH analog that abolished this VIP effect and restored cell
proliferation to basal levels. JV-1-53 is a VIP-receptor antagonist previ-
ously tested in other tumors [24,25,34]. JV-1-53 shows an almost negli-
gible afﬁnity for GHRH receptors, similar to that of VIP. JV-1-53
structure is: [Ac-His1,D-Phe2,Phe(4-Cl)6,Lys15,Arg16,Lys20,Tyr22,Nle27,
D-Arg28,Har29]hGHRH(1–29)NH2. JV-1-53 contains a D-Phe2 substitu-
ent instead of D-Arg2, because this substitution produces a predomi-
nantly VIP antagonistic property on incorporation into GHRH analogs
[24,25]. VIP antagonist JV-1-53 has several additional substitutions
intended to increase the binding to VIP receptors and decrease its afﬁn-
ity to GHRH receptors such as the incorporation of Lys15 (also found in
native VIP) and Arg16 residues [24,25]. Tyr22 increases the binding to
VPAC2 receptors and confers enhanced VPAC2-receptor antagonistic ac-
tivity to the analog in addition to its potent VPAC1-receptor inhibitory
activity. JV-1-53 also contains Lys20 substitution, characteristic of native
VIP. As in other GHRH analogs, Lys20 drastically reduces GH-releasing
activity and decreases the afﬁnity to GHRH receptors. JV-1-53 is not
able to inhibit GHRH-stimulated GH response, and its GHRH-receptor
binding afﬁnity is decreased as compared with GHRH antagonists
JV-1-36 and JV-1-38 [25]. In previous studies, GHRH antagonists
MZ-4-71 ([Ibu-Tyr1,D-Arg2,Phe(4-Cl6),Abu15,Nle27]hGHRH(1–28)
Agm) and JV-1-38 [PhAc-Tyr1,D-Arg2,Phe(4-Cl)6,Har9,Tyr(Me)10,
Abu15,Nle27,D-Arg28,Har29]hGHRH(1–29)NH2) inhibited in vivo growth
of CAKI-1-RCC [35,36]. The antagonist JV-1-53 showed high binding af-
ﬁnity to VIP receptors on CAKI-1 cancer cells [36]. Since the structure of
JV-1-53 is based on GHRH(1–29) and related to those of MZ-4-71 and
JV-1-38, the ﬁndings reported in this paper and contrasted with the
results cited above [35,36] demonstrate a high speciﬁcity of both
the analogs and the receptors for GHRH and VIP.
The evidence for antiproliferative effects of VIP was reinforced by
the silencing of VPAC1 receptor with siRNA which resulted in an almost
complete absence of VPAC1 receptors in renal tumor cells. In addition,
we also observed increases in both cell proliferation and expression of
pSTAT3/STAT3 ratio in transfected cells. Thus, antiproliferative effects
of VIP in A498 cells are initiated by VPAC1 receptors and involve activa-
tion of STAT3. Silencing of VIP receptors by siRNA transfection has been
carried out in a limited number of studies including those on human
prostate epithelial cells [29], breast cancer cells [37] and embryonic
kidney cells [38].
Our experiments show that VIP dose-dependently stimulates
adenylyl cyclase activity in both HK2 and A498 cells. The same pat-
tern was observed by direct activation of the enzyme with forskolin.
Moreover, VIP, forskolin, and the EPAC agonist 8-pCPT-2′-O-Me-cAMPinhibited proliferation of A498 cells, as measured by BrdU incorporation
assays. These results support that the antiproliferative effects of
VIP could be mediated by a cAMP-dependent mechanism in a similar
manner to that seen in other tumors such as neuroblastoma [21] and he-
patocellular carcinoma [22]. In renal tumor cells, the cAMP signal is con-
ceivably connected with STAT3 through PI3‐K transduction pathway as
suggested by the abrogating effect of the PI3‐K inhibitor wortmannin
on antiproliferative activity of VIP. In small cell lung carcinoma [39,40],
VIP inhibited cell proliferation through the cAMP/PKA pathway whereas
the effect of this neuropeptide was cAMP independent in C6 glioma cells
[41]. It is important to note that the observations in vitro on the growth
inhibitory effects of VIPwere conﬁrmed in vivo bymeans of xenografting
of A498 cells (treated with VIP and/or the speciﬁc antagonist JV-1-53) in
athymic nude mice. The observed VIP effect in developing tumors after
subcutaneous injection of VIP-treated A498 cells was a reduction of
tumoral mass of about 30%. The involvement of VPAC1-receptor in
this response was indicated by the reversion of the VIP effect with
cell incubation in the presence of the speciﬁc antagonist JV-1-53.
In conclusion, our results support that the VIP-receptor systemmay
be considered one of the components involved in decreased prolifera-
tion of renal cancer cells, as assessed by the study of VIP treatment in
the incorporation of [3H]-thymidine and BrdU, PCNA expression and
STAT3 expression and activation in tumoral A498 cells. Cell growth-
inhibitory response to VIP involves VPAC1-receptor participation and
appears to be related to the EPAC/PI3-K signaling systems. Moreover,
in vivo results with xenografted athymic nudemice conﬁrm the growth
inhibitory effect of VIP and the involvement of VPAC1 receptor, which
represents the ﬁrst description of an antitumoral effect of VIP in an an-
imal model. Present data must be added to those obtained on the pro-
tective role of the VIP-related peptide PACAP in kidney cells as well as
in multiple myeloma and other kidney diseases [19,20]. Our ﬁndings
suggest the merit of further molecular studies on signaling pathways
and transcriptional factors responsible for tumor growth suppression
aimed at development of effective VIP-related molecules for potential
therapy of renal cell carcinoma.
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